ST Biosciences
ST Bio Sciences is dedicated to unlocking the transformative therapeutic potential of cannabinoid and psychedelic compounds. The company focuses on research, development, and commercialization of synthetic cannabinoid and psilocybin drugs, as well as pharmaceutical-grade natural cannabis products. With active drug pipelines of 14 proprietary compounds, they aim to provide affordable and accessible medicines globally. Their research and development footprint spans 31 markets across North and South America, Asia, and Australia, collaborating with top-tier academic institutions and clinical research organizations to advance drug discovery and trials.
Industries
Nr. of Employees
small (1-50)
ST Biosciences
New York, New York, United States, North America
Products
Proprietary drug development pipeline (14 compounds)
An internally managed pipeline of 14 proprietary therapeutic candidates focused on cannabinoid- and psychedelic-derived mechanisms for multiple clinical indications.
Proprietary drug development pipeline (14 compounds)
An internally managed pipeline of 14 proprietary therapeutic candidates focused on cannabinoid- and psychedelic-derived mechanisms for multiple clinical indications.
Services
Research services to identify and optimize small-molecule and natural-product candidates for therapeutic development.
Coordination and execution of clinical trials through partnerships with recognized clinical research organizations and academic institutions.
In-house manufacture of active pharmaceutical ingredients and development of pharmaceutical-grade formulations, including plant-derived products, for scalable commercial supply.
Quality systems implementation and regulatory affairs support aligned to international pharmaceutical standards (GMP/GLP).
Commercialization planning and distribution capabilities across multiple international markets to support healthcare sales.
Investor communications, SEC filing visibility and financial-alert distribution to stakeholders.
Research services to identify and optimize small-molecule and natural-product candidates for therapeutic development.
Coordination and execution of clinical trials through partnerships with recognized clinical research organizations and academic institutions.
In-house manufacture of active pharmaceutical ingredients and development of pharmaceutical-grade formulations, including plant-derived products, for scalable commercial supply.
Quality systems implementation and regulatory affairs support aligned to international pharmaceutical standards (GMP/GLP).
Commercialization planning and distribution capabilities across multiple international markets to support healthcare sales.
Investor communications, SEC filing visibility and financial-alert distribution to stakeholders.
Expertise Areas
- Cannabinoid and psychedelic therapeutic development
- Preclinical and clinical development
- API manufacturing and formulation development
- Clinical trial management and CRO coordination
Key Technologies
- Small-molecule synthesis for cannabinoid and psychedelic compounds
- Active pharmaceutical ingredient (API) manufacturing
- Pharmaceutical-grade botanical formulation
- Preclinical research and candidate optimization